7,8,9,10-tetrahydrophenanthridine | 62833-92-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 7,8,9,10-tetrahydrophenanthridine
• 英文别名: 7,8,9,10-tetrahydro-phenanthridine；7,8,9,10-Tetrahydro-phenanthridin；7.8.9.10-Tetrahydro-phenanthridin；5.6.7.8-Tetrahydro-phenanthridin
• CAS: 62833-92-5
• 化学式: C₁₃H₁₃N
• mdl: MFCD00848896
• 分子量: 183.253
• InChiKey: OGJFULQWWMMHAA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.307
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  7,8,9,10-tetrahydrophenanthridine 在 2,6-二甲基吡啶 、 4-二甲氨基吡啶 、 potassium cyanide 、 palladium diacetate 、 lithium aluminium tetrahydride 、 copper (I) iodide 、 偶氮二异丁腈 、 4 A molecular sieve 、 四丁基氟化铵 、 三正丁基氢锡 、 potassium carbonate 、 silver nitrate 、 正丁胺 、 间氯过氧苯甲酸 、 三苯基膦 、 pyridinium chlorochromate 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 甲醇 、 乙醚 、 二氯甲烷 、 环己烷 、 甲苯 为溶剂， 反应 92.0h， 生成 (1R,5R,8Z,12R,20S)-21-oxa-13-azapentacyclo[10.9.0.01,20.05,20.014,19]henicosa-8,14,16,18-tetraen-6,10-diyne
  参考文献：
  名称：

  动力霉素 A 模型的合成和化学

  摘要：

  实现了包含氮、烯二炔和环氧化物官能团的动力霉素 A (2) 的模型系统 10 和 22 的合成。显示这些模型在合适的 H 原子供体存在下经历酸诱导触发以产生相应的伯格曼环化产物。从 22 上去除 N 保护基团得到不稳定的 qfree 胺 30，这表明会导致双链 DNA 切割，可能以类似于动力霉素 A (2) 本身的方式。还介绍了与烯二炔的二钴配合物有关的一些有趣的化学反应

  DOI：

  10.1021/ja00008a045
• 作为产物：
  描述：

  1-溴-2-硝基苯 在 四(三苯基膦)钯 、 镍 氢气 、 铜 作用下， 以 乙醇 、 二甲基亚砜 为溶剂， 反应 6.0h， 生成 7,8,9,10-tetrahydrophenanthridine
  参考文献：
  名称：

  New protocols for the synthesis of 3,4-annulated and 4-substituted quinolines from β-bromo-α,β-unsaturated aldehydes and 1-bromo-2-nitrobenzene or 2-bromoacetanilide

  摘要：

  The palladium[0]-mediated Ullmann cross-coupling of readily available beta-bromo-alpha,beta-unsaturated aldehydes of the general form 2 with 1-bromo-2-nitrobenzene (3, X = Br) delivers products, 4, that undergo reductive cyclization to novel quinolines (5) upon exposure to indium in aqueous ammonium chloride or to Raney-nickel in the presence of dihydrogen. Analogous cross-coupling of 2-bromoacetanilide (6) with 2 affords products of type 7 that undergo in situ and K2CO3-mediated cyclization to give the same types of quinolines (5). (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2007.03.078

文献信息

• ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES
  申请人：Universal Display Corporation

  公开号：US20190319198A1

  公开（公告）日：2019-10-17

  An organic light emitting device (OLED) that includes an anode, a cathode, and an organic layer disposed between the anode and the cathode. The organic layer includes a metal compound that comprises a ligand L A of Formula I, wherein the dashed lines represent coordination to a metal M. The metal M is selected from the groups consisting of Os, Ru, Ir, Rh, Pt, Pd, and Cu, and the metal is further coordinated to one or more ligand(s) L B , wherein the ligand(s) L B can be the same or different if more than one ligand L B is present. Optionally one or two of the ligand(s) L B can independently link to the ligand L A through one of R 1 to R 5 . The invention is also directed to a consumer product that includes an OLED, and the OLED includes an organic layer that includes a metal compound that comprises a ligand L A of Formula I.

  一种有机发光器件（OLED），包括阳极、阴极和位于阳极和阴极之间的有机层。有机层包括一个包含配体LA的化合物，其中虚线代表与金属M的配位。金属M选自Os、Ru、Ir、Rh、Pt、Pd和Cu组，金属进一步与一个或多个配体LB配位，如果有多个配体LB，则这些配体LB可以相同或不同。可选地，一个或两个配体LB可以独立地通过R1至R5中的一个连接到配体LA。该发明还涉及一种包括OLED的消费产品，该OLED包括一个包含配体LA的化合物的有机层。
• PLATINUM COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER
  申请人：Blend Therapeutics

  公开号：US20140088066A1

  公开（公告）日：2014-03-27

  The present disclosure relates to novel pharmaceutical compositions comprising a nanoparticle associated with, tether to, or encapsulating a platinum-based active pharmaceutical agent. The platinum-based drug is released from the nanoparticles in a controlled fashion. Also contemplated are methods of making the nanoparticles, as well as methods for using them in the treatment or prevention of diseases or conditions. One embodiment relates to phenanthriplatin nanoparticles and methods of using and making the same.

  本公开涉及新型药物组合物，包括与铂类活性药物相关联、连接或封装的纳米颗粒。铂类药物从纳米颗粒中以受控的方式释放。还考虑了制备纳米颗粒的方法，以及在治疗或预防疾病或病症中使用它们的方法。其中一种实施形式涉及苯并芘铂纳米颗粒及其制备和使用方法。
• Synthesis of dynemicin A models
  作者：K. C. Nicolaou、C. K. Hwang、A. L. Smith、S. V. Wendeborn

  DOI：10.1021/ja00176a064

  日期：1990.9
• Visible-Light-Promoted and One-Pot Synthesis of Phenanthridines and Quinolines from Aldehydes and <i>O</i>-Acyl Hydroxylamine
  作者：Xiao-De An、Shouyun Yu

  DOI：10.1021/acs.orglett.5b01096

  日期：2015.6.5

  A one-pot synthesis of phenanthridines and quinolines from commercially available or easily prepared aldehydes has been reported. O-(4-Cyanobenzoyl)hydroxylamine was utilized as the nitrogen source to generate O-acyl oximes in situ with aldehydes catalyzed by Bronsted acid. O-Acyl oximes were then subjected to visible light photoredox catalyzed cyclization via iminyl radicals to furnish aza-arenes. A variety of phenanthridines and quinolines have been prepared assisted by Bronsted acid and photocatalyst under visible light at room temperature with satisfactory yields.
• [EN] PLATINUM COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER<br/>[FR] COMPOSÉS DE PLATINE, COMPOSITIONS ET PROCÉDÉS DE TRAITEMENT DU CANCER
  申请人：BLEND THERAPEUTICS

  公开号：WO2014043243A3

  公开（公告）日：2015-07-16